Sheila Moran serves as Sema4’s Senior Vice President, Solution Sales. During her career, she has held dual roles in operations, marketing and product development enabling her to bring a deeper level of experience to growing emerging businesses as well as driving new growth in established businesses.
Prior to Sema4, she was VP of Sales for the Therapy division of Source Medical leading Software and Revenue Cycle Management, culminating in the successful sale of the business. She previously held a variety of leadership positions domestically and globally over a 20-year tenure at IBM.
Chief Commercial Officer
Thomas A. Neyarapally is an expert in commercial strategy, organizational development, and business growth. He serves as Sema4’s Chief Commercial Officer and is responsible for further building partnerships with biopharmaceutical companies to provide data-driven insights, which accelerate drug discovery and development across the clinical disease spectrum.
Tom joined Sema4 from GNS Healthcare, a healthcare analytics company, where he was a member of the founding team and Executive Vice President, Corporate Development.
Tom received his degree in chemical engineering, cum laude, and as an Honors Scholar, from the University of Connecticut, as well as J.D. and M.B.A. degrees from Cornell University.
SVP & GM, Research Business Unit
Qi Pan, Ph.D., has over 16 years of experience in biotech and pharmaceutical Research & Development (R&D), with an in-depth knowledge of oncology and biotherapeutic drug discovery and development. As the Senior Vice President and General Manager of Research at Sema4, Qi is responsible for driving the next wave of research-led advances to augment our competitive edge, as well as delivering high priority research projects. She was promoted to her current role from Vice President in 2020.
Prior to Sema4, Qi was Vice President of R&D at Legend Biotech, a leading biotech company, overseeing the discovery of innovative CAR-T therapy to treat cancer. Prior to that, Qi worked at leading pharmaceutical companies including Genentech and Boehringer Ingelheim on biotherapeutics discovery.
Qi received her Ph.D. from Harvard University in the field of molecular and cellular biology.
SVP, Business Development
Matt Phillips serves as Senior Vice President, Business Development for Sema4. He is recognized as an expert in patient and provider engagement, partnership strategy and launching new business to market focused on healthcare outcomes.
Prior to joining Sema4, Matt was Senior Vice President of Business Development of Surgical Information Systems. He also led business development activities at Dell for more than 15 years.
SVP & GM, Women’s Health
Bridget Winders serves as Sema4’s Senior Vice President and General Manager, Women’s Health. Bridget has over 20 years of expertise in business and go-to-market strategy, services and sales in industries ranging from healthcare, education, government, and financial. In various leadership roles, she has built diverse, multi-disciplinary teams for business effective operations.
Prior to Sema4, Bridget was Vice President of the Central and Pacific Northwest region for Dell | EMC and Dell’s Healthcare and Life Sciences organization focused on delivering quality outcomes with data analytics and broad IT solutions.